REMIND is a phase III study of the molecule Remibrutinib for controlling chronic urticaria that is uncontrolled by antihistamines.
You may receive the investigational molecule or a placebo. The treatment is administered orally.
To participate, you must have received a diagnosis of chronic urticaria.
Clic here to access the official record from the National Library of Medicine for this study